Midostaurin has also been evaluated in combination with liposomal daunorubicin and cytarabine (CPX-351) in newly diagnosed adults with FLT3-mutated AML up to age 75; preliminary results of 23 patients indicate this regimen is safe and efficacious, with a complete response (CR) rate of 82% [27]. Here, FLT3 is linked to acute myeloid leukemia.